Intensification of glucose-lowering therapy for type 2 diabetes mellitus using insulin degludec: clinical case analysis

The article discusses a clinical case of intensification of glucose-lowering therapy with insulin degludec in a patient with type 2 diabetes mellitus (DM2); who did not achieve glycemic control goals despite the use of a combination of three glucose-lowering drugs: metformin; empagliflozin and semaglutide. Fasting and postprandial glycemia was more than 10 mmol/l; the glycated hemoglobin level was 10.4%. In addition; the time above the target range was 85%; and no hypoglycemic conditions were recorded. After intensifying hypoglycemic therapy with insulin degludec; a significant improvement in glycemic control was noted: fasting glucose was 5.4–6.2 mmol/l; postprandial – up to 10 mmol/l; the time in the target range; according to flash data. monitoring was 99%; no hypoglycemic conditions were noted.